

The logo for PHARMAC (Te Pātaka Whaioranga) is a white circle containing the text 'PHARMAC' in a large, bold, sans-serif font, with 'TE PĀTAKA WHAIORANGA' in a smaller, all-caps, sans-serif font below it. The background of the entire page is a grey-to-white gradient with a large, intricate, white geometric pattern of concentric, overlapping lines that form a complex, maze-like or cellular structure.

PHARMAC
TE PĀTAKA WHAIORANGA

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Update

April 2023

Contents

Summary of Pharmac decisions effective 1 April 2023	3
Tender News	5
Looking Forward	5
Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023.....	6
New Listings.....	20
Changes to Restrictions, Chemical Names and Presentations	24
Changes to Subsidy and Manufacturer’s Price.....	28
Delisted Items	30
Items to be Delisted	32
Index.....	33

Summary of Pharmac decisions

EFFECTIVE 1 APRIL 2023

New listings (pages 20-22)

- Glycopyrronium bromide (Robinul) inj 200 mcg per ml, 1 ml ampoule – up to 10 inj available on PSO
- Hydroxocobalamin (Cobal-B12) inj 1 mg per ml, 1 ml ampoule – up to 6 inj available on a PSO, s29 and wastage claimable
- Water (Multichem) inj 10 ml ampoule – up to 5 inj available on a PSO
- Enalapril maleate (Acetec) tab 5 mg, 10 mg and 20 mg, 90 tab packs
- Darunavir (Darunavir Viatrix) tab 400 mg – Special Authority – Retail Pharmacy
- Phenytoin sodium (Dilantin Infatab) tab 50 mg, new pharmacode
- Atezolizumab inj 60 mg per ml, 20 ml vial (Tecentriq) and inj 1 mg for ECP (Baxter) – PCT only – Specialist – Special Authority
- Elexacaftor with tezacaftor, ivacaftor and ivacaftor (Trikafta) tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg and ivacaftor 75 mg and tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg and ivacaftor 150 mg – PCT only – Special Authority
- Chloramphenicol (Chlorsig) eye drops 0.5%, 10 ml OP

Changes to restrictions (pages 24-27)

- Pyridoxine hydrochloride (Pyridoxine multichem) tab 50 mg – reinstate stat dispensing
- Folic acid (Folic Acid multichem) tab 0.8 mg – reinstate stat dispensing
- Melatonin (Vigisom) tab modified-release 2 mg – addition of age restriction
- Pembrolizumab inj 25 mg per ml, 4 ml vial (Keytruda) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Timolol (Timoptol XE) eye drops 0.5%, gel forming, 2.5 ml OP – addition of subsidy by endorsement
- Dorzolamide hydrochloride (Trusopt) eye drops 2%, 5 ml OP – addition of subsidy by endorsement
- Influenza vaccine (Afluria Quad Junior (2023 formulation)) inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) – amended restriction criteria
- Influenza vaccine (Afluria Quad (2023 formulation)) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – amended restriction criteria and addition of maximum of 1 inj per prescription

Summary of Pharmac decisions – effective 1 April 2023 (continued)

Increased subsidy (page 28)

- Sodium cromoglycate (Ralicrom) cap 100 mg
- Folic acid (Biomed) oral liq 50 mcg per ml, 25 ml OP
- Heparin sodium (Pfizer) inj 5000 iu per ml, 5 ml ampoule
- Sodium bicarbonate (Biomed) inj 8.4%, 50 ml and 100 ml
- Spironolactone (Biomed) oral liq 5 mg per ml, 25 ml OP
- Dexamethasone (Biomed) oral liq 1 mg per ml, 25 ml OP
- Lidocaine [Lignocaine] hydrochloride (Mucosoothe) oral (gel) soln 2%, 200 ml
- Levetiracetam (Everet) tab 250 mg, 500 mg, 750 mg and 1,000 mg

Decreased subsidy (pages 28-29)

- Fluconazole (Diflucan) powder for oral suspension 10 mg per ml, 35 ml
- Pembrolizumab (Baxter) inj 1 mg for ECP
- Cetirizine hydrochloride (Zista) tab 10 mg

Increased price but not subsidy (page 28)

- Benzydamine hydrochloride (Difflam) soln 0.15%, 500 ml
- Mebendazole (Vermox) oral liq 100 mg per 5 ml, 15 ml

Tender News

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) changes – effective 1 May 2023

Chemical Name	Presentation; Pack size	PSS/SSS	PSS/SSS brand (and supplier)
Abacavir sulphate with lamivudine	Tab 600mg with 30mg; 30 tab	PSS	Abacavir/Lamivudine Viatris (Viatris)
Atazanavir Sulphate	Cap 150 mg; 60 cap	PSS	Atazanavir Mylan (Viatris)
Atazanavir sulphate	Cap 200 mg; 60 cap	PSS	Atazanavir Mylan (Viatris)
Clopidogrel	Tab 75 mg; 84 tab	PSS	Arrow – Clopid (Teva)
Codeine phosphate	Tab 15 mg; 100 tab	PSS	Noumed (Noumed)
Nortriptyline hydrochloride	Tab 10 mg; 100 tab	PSS	Norpress (Viatris)
Nortriptyline hydrochloride	Tab 25 mg; 180 tab	PSS	Norpress (Viatris)
Paraffin	Oint liquid paraffin 50% with white soft paraffin 50%; 500 g OP	PSS	White Soft Liquid Paraffin AFT (AFT)
Posaconazole	Oral liq 40 mg per ml; 105 ml OP	PSS	Devatis (Devatis)
Progesterone	Cap 100 mg; 30 cap	PSS	Utrogestan (Pharmaco)
Ramipril	Cap 1.25 mg; 30 cap	PSS	Tryzan (Viatris)
Ramipril	Cap 2.5 mg; 30 cap	PSS	Tryzan (Viatris)
Ramipril	Cap 5 mg; 30 cap	PSS	Tryzan (Viatris)
Ramipril	Cap 10 mg; 30 cap	PSS	Tryzan (Viatris)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Decisions for implementation 1 May 2023

- Dexamfetamine sulphate (Noumed) tab 5 mg – new listing
- Oxaliplatin (Alchemy Oxaliplatin) inj 5 mg per ml, 20 ml vial – new listing
- Pharmacy services (BSF Abacavir/ Lamivudine Viatris) brand switch fee – new listing
- Phenobarbitone (Noumed Phenobarbitone) tab 15 mg and 30 mg – new listing
- Vinorelbine (Vinorelbine Te Arai) cap 20 mg, 30 mg and 80 mg – new listing

Possible decisions for future implementation 1 May 2023

- Risdiplam (Evrysdi) powder for oral solution, 750 mcg per ml, 60 mg per bottle, 80 ml OP – new listing with Special Authority and Xpharm

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Acarbose	Tab 50 mg & 100 mg	Accarb	2024
Acetylcysteine	Inj 200 mg per ml, 10 ml ampoule	Martindale Pharma	2024
Aciclovir	Tab dispersible 400 mg & 800 mg Tab dispersible 200 mg Eye oint 3%, 4.5 g OP	Lovir VirusPOS	2025 2024
Acitretin	Cap 10 mg & 25 mg	Novatretin	2023
Adalimumab (Amgevita)	Inj 20 mg per 0.4 ml prefilled syringe, inj 40 mg per 0.8 ml prefilled syringe & inj 40 mg per 0.8 ml prefilled pen	Amgevita	31/07/2026
Allopurinol	Tab 100 mg & 300 mg	DP-Allopurinol	2023
Ambrisentan	Tab 5 mg & 10 mg	Ambrisentan Mylan	2023
Amiodarone hydrochloride	Inj 50 mg per ml, 3 ml ampoule Tab 100 mg & 200 mg	Max Health Aratac	2025
Amitriptyline	Tab 10 mg, 25 mg & 50 mg	Arrow-Amitriptyline	2023
Amlodipine	Tab 2.5 mg, 5 mg & 10 mg	Vasorex	2023
Amorolfine	Nail soln 5%, 5 ml OP	MycosNail	2023
Amoxicillin	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Alphamox 125 Alphamox 250	2023
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg	Curam Duo 500/125	2023
Anastrozole	Tab 1 mg	Anatrole	2023
Apomorphine hydrochloride	Inj 10 mg per ml, 5 ml ampoule Inj 10 mg per ml, 2 ml ampoule	Movapo	2023
Aprepitant	Cap 2 x 80 mg and 1 x 125 mg	Emend Tripack	2024
Aqueous cream	Crn, 500 g	GEM Aqueous Cream	2024
Ascorbic acid	Tab 100 mg	CVite	2025
Atenolol	Tab 50 mg & 100 mg	Mylan Atenolol	2024
Atorvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Lorstat	2024
Atropine sulphate	Inj 600 mcg per ml, 1 ml ampoule Eye drops 1%, 15 ml OP	Martindale Atropt	2024 2023
Azathioprine	Tab 25 mg Tab 50 mg	Azamun	2025
Azithromycin	Tab 500 mg	Zithromax	2024
Bacillus calmette-guerin vaccine	Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent	BCG Vaccine	2024
Baclofen	Inj 2 mg per ml, 5 ml ampoule	Medsurge	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Bendroflumethiazide [Bendrofluazide]	Tab 2.5 mg & 5 mg	Arrow- Bendrofluazide	2023
Benzatropine mesylate	Inj 1 mg per ml, 2 ml	Phebra	2023
Benzylpenicillin sodium [Penicillin G]	Inj 600 mg (1 million units) vial	Sandoz	2023
Betahistidine dihydrochloride	Tab 16 mg	Serc	2023
Betamethasone dipropionate	Crn & oint 0.05%, 50 g OP	Diprosone	2023
Betamethasone dipropionate with calcipotriol	Oint 500 mcg with calcipotriol 50 mcg per g, 30 g OP Gel 500 mcg with calcipotriol 50 mcg per g, 60 g OP	Daivobet	2024
Betamethasone valerate	Lotn 0.1%, 50 ml OP Oint 0.1%, 50 g OP Crn 0.1%, 50 g OP Scalp app 0.1%, 100 ml OP	Betnovate Beta Ointment Beta Cream Beta Scalp	2024
Bicalutamide	Tab 50 mg	Binarex	2023
Bimatoprost	Eye drops 0.03%, 3 ml OP	Bimatoprost Multichem	2024
Bisacodyl	Tab 5 mg Suppos 10 mg	Bisacodyl Viatris Pharmacy Health Lax-suppositories	2025 2024
Bisoprolol fumarate	Tab 2.5 mg, 5 mg & 10 mg	Bisoprolol Mylan	2023
Bosentan	Tab 62.5 mg & 125 mg	Bosentan Dr Reddy's	2024
Brimonidine tartrate	Eye drops 0.2%, 5 ml OP	Arrow-Brimonidine	2024
Brinzolamide	Eye drops 1%, 5 ml OP	Azopt	2024
Budesonide	Metered aqueous nasal spray, 50 mcg & 100 mcg per dose, 200 dose OP	SteroClear	2023
Bupropion hydrochloride	Tab modified-release 150 mg	Zyban	2023
Bezafibrate	Tab 200 mg Tab long-acting 400 mg	Bezalip Bezalip Retard	2024
Buprenorphine with naloxone	Tab sublingual 2 mg with naloxone 0.5 mg & 8 mg with naloxone 2 mg	Buprenorphine Naloxone BNM	2025
Buspirone hydrochloride	Tab 5 mg & 10 mg	Buspirone Viatris	2024
Calamine	Crn, aqueous, BP, 100 g	Calamine-AFT	2024
Calcitriol	Cap 0.25 mcg & 0.5 mcg	Calcitriol-AFT	2025
Calcium carbonate	Tab 1.25 g (500 mg elemental)	Calci-Tab 500	2023
Candesartan cilexetil	Tab 4 mg, 8 mg, 16 mg & 32 mg	Candestar	2024
Capsaicin	Crn 0.025%, 45 g OP Crn 0.075%, 45 g OP	Zostrix Zostrix HP	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Carbimazole	Tab 5 mg	Neo-Mercazole	2025
Cefaclor monohydrate	Cap 250 mg Grans for oral liq 125 mg per 5 ml	Ranbaxy Cefaclor	2025
Cefalexin	Cap 250 mg & 500 mg Grans for oral liq 25 mg per ml & 50 mg per ml	Cephalexin ABM Flynn	2025 2024
Cefazolin	Inj 500 mg & 1 g vial	AFT	2023
Ceftriaxone	Inj 500 mg & 1 g vial	Ceftriaxone-AFT	2025
Celecoxib	Cap 100 mg & 200 mg	Celecoxib Pfizer	2025
Cetirizine hydrochloride	Oral liq 1 mg per ml, 200 ml	Hisatclear	2024
Cetomacrogol	Crn BP, 500 g	Cetomacrogol-AFT	2024
Chloramphenicol	Eye oint 1%, 5 g OP	Devatis	2025
Chlortalidone [Chlorthalidone]	Tab 25 mg	Hygroton	2025
Cinacalcet	Tab 30 mg & 60 mg	Cinacalcet Devatis	2024
Ciprofloxacin	Eye drops 0.3%, 5 ml OP Tab 250 mg, 500 mg & 750 mg	Ciprofloxacin Teva Cipflox	2024 2023
Citalopram hydrobromide	Tab 20 mg	Celapram PSM Citalopram	2025 2024
Clarithromycin	Tab 250 mg & 500 mg	Klacid	2024
Clobetasol propionate	Crn & oint 0.05%, 30 g OP Scalp app 0.05%, 30 ml OP	Dermol	2025
Clomipramine hydrochloride	Tab 10 mg & 25 mg	Clomipramine Teva	2024
Clonidine	Patch 2.5 mg, 100 mcg per day Patch 5 mg, 200 mcg per day Patch 7.5 mg, 300 mcg per day	Mylan	2023
Clonidine hydrochloride	Tab 25 mcg Inj 150 mcg per ml, 1 ml ampoule Tab 150 mcg	Clonidine Teva Medsurge Catapres	2025 2024
Clotrimazole	Vaginal crm 1% with applicators, 35 g OP Vaginal crm 2% with applicators, 20 g OP Crn 1%, 20 g OP	Clomazol	2025
Codeine phosphate	Tab 30 mg & 60 mg Tab 15 mg, 30 mg & 60 mg	Noumed PSM	2025 2023
Colchicine	Tab 500 mcg	Colgout	2025
Colecalciferol	Cap 1.25 mg (50,000 iu)	Vit.D3	2023
Compound electrolytes	Powder for oral soln	Electral	2025
Crotamiton	Crn 10%, 20 g OP	Itch-soothe	2024
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Cyclizine lactate	Inj 50 mg per ml, 1 ml ampoule	Hameln	2025
Cyclophosphamide	Tab 50 mg	Cylconex	2024
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2024
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	Ginet	2023
Darunavir	Tab 400 mg & 600 mg	Darunavir Mylan	2023
Desmopressin acetate	Nasal spray 10 mcg per dos, 6 ml OP	Desmopressin-PH&T	2023
Dexamethasone	Tab 0.5 mg & 4 mg	Dexmethsone	2024
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml & 2 ml ampoule	Hameln	2025
Dexamfetamine sulfate	Tab 5 mg	PSM	2024
Diazepam	Rectal tubes 5 mg Tab 2 mg & 5 mg	Stesolid Arrow-Diazepam	2025 2023
Diclofenac	Eye drops 0.1%, 5 ml OP	Voltaren Ophtha	2024
Diclofenac sodium	Tab EC 25 mg & 50 mg	Diclofenac Sandoz	2024
Digoxin	Tab 62.5 mcg Tab 250 mcg	Lanoxin PG Lanoxin	2025
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2025
Diltiazem hydrochloride	Cap long-acting 180 mg & 240 mg	Cardizem CD	2024
Dimethicone	Crn 5% pump bottle, 500 ml OP Lotn 4%, 200 ml OP	healthE Dimethicone 5% healthE Dimethicone 4%	2025
Diphtheria, tetanus and pertussis vaccine	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe	Boostrix	2024
Diphtheria, tetanus, pertussis and polio vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe	Infanrix IPV	2024
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-AgU polio virus, 10 mcg hepatitis B surface antigen in 0.5ml syringe	Infanrix-hexa	2024
Disulfiram	Tab 200 mg	Antabuse	2024
Docusate sodium	Tab 50 mg & 120 mg	Coloxyl	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Docusate sodium with sennosides	Tab 50 mg with sennosides 8 mg	Laxsol	2025
Domperidone	Tab 10 mg	Pharmacy Health	2024
Donepezil hydrochloride	Tab 5 mg & 10 mg	Donepezil-Rex	2023
Dorzolamide with timolol	Eye drops 2% with timolol 0.5%, 5 ml OP	Dortimopt	2024
Emtricitabine with tenofovir disoproxil	Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate)	Tenofovir Disoproxil Emtricitabine Mylan	2025
Emulsifying ointment	Oint BP	Emulsifying Ointment ADE	2023
Entacapone	Tab 200 mg	Comtan	2024
Eplerenone	Tab 25 mg & 50 mg	Inspra	2024
Erlotinib	Tab 100 mg & 150 mg	Alchemy	2023
Erythromycin (as lactobionate)	Inj 1 g	Erythromycin IV	2025
Escitalopram	Tab 10 mg & 20 mg	Escitalopram (Ethics)	2024
Etanercept	Inj 25 mg Inj 50 mg autoinjector Inj 50 mg prefilled syringe	Enbrel	2024
Ezetimibe	Tab 10 mg	Ezetimibe Sandoz	2023
Febuxostat	Tab 80 mg & 120 mg	Febuxostat multichem	2023
Felodipine	Tab long-acting 5 mg Tab long-acting 10 mg	Felo 5 ER Felo 10 ER	2024
Fentanyl	Inj 50 mcg per ml, 2ml ampoule Inj 50 mcg per ml, 10 ml ampoule Patch 12.5 mcg per hour Patch 25 mcg per hour Patch 50 mcg per hour Patch 75 mcg per hour Patch 100 mcg per hour	Boucher and Muir Fentanyl Sandoz	2024
Ferrous fumarate	Tab 200 mg (65 mg elemental)	Ferro-tab	2024
Ferrous fumarate with folic acid	Tab 310 mg (100 mg elemental) with folic acid 350 mcg	Ferro-F-Tabs	2024
Ferrous sulfate	Tab long-acting 325 mg (105 mg elemental) Oral liq 30 mg (6 mg elemental) per ml	Ferrograd Ferodan	2025
Filgrastim	Inj 300 mcg per 0.5 ml & 480 mcg per 0.5 ml	Nivestim	2024
Finasteride	Tab 5 mg	Ricit	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Flucloxacillin	Cap 250 mg & 500 mg Grans for oral liq 25 mg per ml Grans for oral liq 50 mg per ml Inj 1 g vial	Flucloxacillin-AFT AFT	2024
		Flucil	2023
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Mylan	2023
Fludrocortisone acetate	Tab 100 mcg	Florinef	2025
Fluorouracil sodium	Crn 5%, 20 g OP	Efudix	2024
Fluoxetine hydrochloride	Tab dispersible 20 mg, scored	Fluox	2025
Fluticasone	Aerosol inhaler 50 mcg, 125 mcg & 250 mcg per dose, 120 dose OP	Flixotide	2023
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose, 120 dose OP	Flixonase Hayfever & Allergy	2024
Fluticasone with salmeterol	Aerosol inhaler 50 mcg with salmeterol 25 mcg & 125 mcg with salmeterol 25 mcg, 120 dose OP	Seretide	2023
Folic acid	Tab 5 mg	Folic Acid Mylan	2024
Furosemide [Frusemide]	Inj 10 mg per ml, 2 ml ampoule Tab 40 mg	Furosemide-Baxter	2025
		IPCA-Frusemide	2024
Gabapentin	Cap 100 mg, 300 mg & 400 mg	Nupentin	2024
Glatiramer acetate	Inj 40 mg prefilled syringe	Copaxone	2025
Glibenclamide	Tab 5 mg	Daonil	2024
Gliclazide	Tab 80 mg	Glizide	2023
Glipizide	Tab 5 mg	Minidiab	2024
Glucagon hydrochloride	Inj 1 mg syringe kit	Glucagen Hypokit	2023
Glucose [Dextrose]	Inj 50%, 10 ml ampoule Inj 50%, 90 ml bottle	Biomed	2023
Glycerol	Suppos 4 g Liquid	Lax suppositories Glycerol	2025
		healthE Glycerol BP	2023
Glyceryl trinitrate	Oint 0.2%, 30 g OP	Rectogesic	2024
Goserelin	Implant 3.6 mg & 10.8 mg, syringe	Teva	2023
Hepatitis A vaccine	Inj 1440 ELISA units in 1 ml syringe Inj 720 ELISA units in 0.5 ml syringe	Havrix	2024
		Havrix Junior	
Hepatitis B recombinant vaccine	Inj 20 mcg per 1 ml prefilled syringe	Engerix-B	2024
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]	Inj 270 mg in 0.5 ml syringe	Gardasil 9	2024
Hydrocortisone	Crn 1%; 30 g OP Inj 100 mg vial	Ethics Solu-Cortef	2025 2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Hydrocortisone and paraffin liquid and lanolin	Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%	DP Lotn HC	2023
Hydrocortisone butyrate	Oint 0.1%, 100 g OP Scalp lotn 0.1%, 100 ml OP Milky emuls 0.1%, 100 ml OP	Locoid Locoid Crelo	2024
Hydrocortisone with miconazole	Crn 1% with miconazole 2%, 15 g OP	Micreme H	2024
Hydroxocobalamin	Inj 1 mg per ml, 1 ml ampoule	Hydroxocobalamin Panpharma	2024
Hydroxyurea [hydroxycarbamide]	Cap 500 mg	Devatis	2023
Hyoscine butylbromide	Tab 10 mg Inj 20 mg, 1 ml	Buscopan	2023
Ibuprofen	Oral liq 20 mg per ml, 200 ml Tab long-acting 800 mg Tab 200 mg	Ethics Brufen SR Relieve	2024
Iloprost	Nebuliser soln 10 mcg per ml, 2 ml	Vebulis	2025
Imatinib mesylate	Cap 100 mg & 400 mg	Imatinib-Rex	2023
Indapamide	Tab 2.5 mg	Dapa-Tabs	2023
Intra-uterine device	IUD 29.1 mm length x 23.2 mm width IUD 33.6 mm length x 29.9 mm width IUD 35.5 mm length x 19.6 mm width	Choice TT380 Short Choice TT380 Standard Choice Load 375	2025
Ipratropium bromide	Aqueous nasal spray, 0.03%, 15 ml OP	Univent	2023
Isoniazid	Tab 100 mg	PSM	2024
Isoniazid with rifampicin	Tab 100 mg with rifampicin 150 mg Tab 150 mg with rifampicin 300 mg	Rifinah	2024
Isosorbide mononitrate	Tab 20 mg Tab long-acting 40 mg Tab long-acting 60 mg	ISMO 20 ISMO 40 Retard Duride	2023
Isotretinoin	Cap 5 mg, 10 mg & 20 mg	Oratane	2024
Ispaghula (psyllium) husk	Powder for oral soln, 500 g OP	Konsyl-D	2023
Ketoconazole	Shampoo 2%, 100 ml OP	Sebizole	2023
Labetalol	Tab 100 mg & 200 mg	Trandate	2024
Lactulose	Oral liq 10 g per 15 ml, 500 ml	Laevolac	2025
Lamivudine	Tab 100 mg Tab 150 mg	Zetlam Lamivudine Alphapharm	2023
Lansoprazole	Cap 15 mg & 30 mg	Lanzol Relief	2024
Latanoprost	Eye drop 0.005%, 2.5 ml OP	Teva	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Latanoprost with timolol	Eye drops 0.005% with timolol 0.5%, 2.5 ml OP	Arrow - Lattim	2023
Leflunomide	Tab 10 mg & 20 mg	Arava	2023
Letrozole	Tab 2.5 mg	Letrole	2024
Levodopa with carbidopa	Tab long-acting 200 mg with carbidopa 50 mg Tab 100 mg with carbidopa 25 mg & 250 mg with carbidopa 25 mg	Sinemet CR Sinemet	2023
Levomepromazine hydrochloride	Inj 25 mg per ml, 1 ml ampoule	Wockhardt	2025
Levonorgestrel	Subdermal implant (2 x 75 mg rods)	Jadelle	2023
Lidocaine [Lignocaine]	Gel 2%, 11 ml urethral syringe	Instillagel lido	2025
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Ethics Lisinopril	2025
Lithium carbonate	Tab long-acting 400 mg	Priadel	2024
Loperamide hydrochloride	Cap 2 mg	Diamide Relief	2025
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg	Lopinavir/Ritonavir Mylan	2024
Loratadine	Tab 10 mg	Lorafix	2025
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2024
Losartan potassium	Tab 12.5 mg, 25 mg, 50 mg & 100 mg	Losartan Actavis	2023
Losartan potassium with hydrochlorothiazide	Tab 50 mg with hydrochlorothiazide 12.5 mg	Arrow-Losartan & Hydrochlorothiazide	2025
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	Molaxole	2023
Magnesium sulphate	Inj 2 mmol per ml, 5 ml ampoule	Martindale	2023
Measles, mumps and rubella vaccine	Inj, measles virus 1,000 CCID ₅₀ , mumps virus 5,012 CCID ₅₀ , Rubella virus 1,000 CCID ₅₀ ; prefilled syringe/ampoule of diluent 0.5 ml	Priorix	2024
Mebendazole	Tab 100 mg	Vermox	2024
Mebeverine hydrochloride	Tab 135 mg	Colofac	2023
Melatonin	Tab modified-release 2 mg	Vigisom	2024
Meningococcal (groups A, C, Y and W-135) conjugate vaccine	Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial	Menactra	2024
Mercaptopurine	Tab 50 mg	Puri-nethol	2025

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Mesalazine	Tab long-acting 500 mg	Pentasa	2023
Metformin hydrochloride	Tab immediate-release 500 mg	Metformin Viatrix	2024
Methadone	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	Biodone Biodone Forte Biodone Extra Forte	2024
Methadone hydrochloride	Tab 5 mg	Methadone BNM	2025
Methenamine (hexamine) hippurate	Tab 1 g	Hiprex	2025
Methotrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 50 ml vial	Trexate Methotrexate Ebewe	2024 2023
Methylprednisolone aceponate	Crn & oint 0.1%, 15 g OP	Advantan	2023
Metoclopramide	Inj 5 mg per ml, 2 ml ampoule	Baxter	2025
Metoclopramide hydrochloride	Tab 10 mg	Metoclopramide Actavis 10	2023
Metoprolol tartrate	Tab 50 mg & 100 mg	IPCA-Metoprolol	2024
Metronidazole	Tab 200 mg & 400 mg	Metrogyl	2023
Metyrapone	Cap 250 mg	Metopirone	2023
Miconazole	Oral gel 20 mg per g, 40 g OP	Decozol	2024
Miconazole nitrate	Crn 2%, 15 g OP Vaginal crn 2% with applicator, 40 g OP	Multichem Micreme	2023
Mirtazapine	Tab 30 mg & 45 mg	Noumed	2024
Moclobemide	Tab 150 mg & 300 mg	Aurorix	2024
Modafinil	Tab 100 mg	Modavigil	2024
Mometasone furoate	Crn 0.1%, 15 g OP Crn 0.1%, 50 g OP Oint 0.1%, 15 g OP Oint 0.1%, 50 g OP Lotn 0.1%, 30 ml OP	Elocon Alcohol Free Elocon	2024
Montelukast	Tab 4 mg, 5 mg & 10 mg	Montelukast Mylan	2025
Morphine sulphate	Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg Inj 5 mg per ml, 1 ml ampoule Inj 10 mg per ml, 1 ml ampoule Inj 15 mg per ml, 1 ml ampoule Inj 30 mg per ml, 1 ml ampoule Tab immediate-release 10 mg & 20 mg	m-Eslon Medsurge Sevredol	2025 2023
Moxifloxacin	Tab 400 mg	Avelox	2023
Multivitamins	Tab (BPC cap strength)	Mvite	2025
Nadolol	Tab 40 mg & 80 mg	Nadolol BNM	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Naloxone hydrochloride	Inj 400 mcg per ml, 1 ml ampoule	Hamelin	2024
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	2023
Naproxen	Tab 250 mg	Noflam 250	2024
	Tab 500 mg	Noflam 500	
	Tab long-acting 750 mg	Naprosyn SR 750	
	Tab long-acting 1 g	Naprosyn SR 1000	
Neostigmine metilsulfate	Inj 2.5 mg per ml, 1 ml ampoule	Max Health	2024
Nevirapine	Tab 200 mg	Nevirapine Alphapharm	2024
Nitrofurantoin	Tab 50 mg & 100 mg	Nifuran	2024
	Cap modified-release 100 mg	Macrobid	2023
Norethisterone	Tab 350 mcg	Noriday 28	2024
Nystatin	Oral liq 100,000 u per ml, 24 ml OP Vaginal crm 100,000 u per 5 g with applicator(s), 75 g OP	Nilstat	2023
Octreotide	Inj 50 mcg per ml, 1 ml ampoule	Max Health	2024
	Inj 100 mcg per ml, 1 ml ampoule		
	Inj 500 mcg per ml, 1 ml ampoule		
Octreotide long-acting	Inj depot 10 mg, 20 mg & 30 mg prefilled syringe	Octreotide Depot Teva	2024
Oestriol	Crn 1 mg per g with applicator, 15 g OP	Ovestin	2023
	Pessaries 500 mcg	Ovestin	
	Tab 2 mg		
Oil in water emulsion	Crn, 500 g	Fatty Cream AFT	2024
Olanzapine	Orodispersible tab 5 mg & 10 mg	Zypine ODT	2023
	Tab 2.5 mg, 5 mg and 10 mg	Zypine	
Olopatadine	Eye drops 0.1%, 5 ml OP	Olopatadine Teva	2025
Omeprazole	Inj 40 mg ampoule with diluent	Dr Reddy's Omeprazole	2025
	Cap 10 mg	Omeprazole actavis 10	2023
	Cap 20 mg	Omeprazole actavis 20	
	Cap 40 mg	Omeprazole actavis 40	
Ondansetron	Tab disp 4 mg & 8 mg	Ondansetron ODT- DRLA	2023
Ornidazole	Tab 500 mg	Arrow-Ornidazole	2024
Orphenadrine citrate	Tab 100 mg	Norflex	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml and 2 ml ampoule	Hameln	2024
	Inj 50 mg per ml, 1 ml ampoule	Oxycodone Sandoz	
	Tab controlled-release 5 mg, 10 mg, 20 mg, 40 mg & 80 mg		
	Cap immediate-release 5 mg, 10 mg & 20 mg Oral liq 5 mg per 5 ml	OxyNorm	
Oxytocin with ergometrine maleate	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule	Syntometrine	2025
Pancreatic enzyme	Cap prncreatin 150 mg (amylase 8,000 Ph Eur U lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)	Creon 10000	2024
	Cap prncreatin 300 mg (amylase 18,000 Ph Eur U lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U)	Creon 25000	
Paracetamol	Oral liq 250 mg per ml, 200 ml Tab 500 mg-bottle pack Tab 500 mg-blister pack Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml	Pamol	2025
		Noumed Paracetamol	2024
		Pacimol	
		Paracare Paracare Double Strength	2023
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 8 mg	Paracetamol + Codeine	2025
Paroxetine	Tab 20 mg	Loxamine	2025
Perindopril	Tab 2 mg & 4 mg	Coversyl	2024
Permethrin	Crn 5%, 30 g OP	Lyderm A-Scabies	2023
	Lotn 5%, 30 ml OP		
Pethidine hydrochloride	Tab 50 mg	PSM	2024
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml & 250 mg per 5 ml	AFT	2025
	Cap 250 mg Cap 500 mg	Cilicaine VK	2024
Pimecrolimus	Crn 1%, 15 g OP	Elidel	2023
Pine tar with trolamine laurilsulfate and fluorescein	Soln 2.3% with trolamine laurilsulfate and fluorescein sodium	Pinetarsol	2023
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Vexazone	2024
Pneumococcal (PCV10) conjugate vaccine	Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe	Synflorix	2024
Pneumococcal (PPV23) polysaccharide vaccine	Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)	Pneumovax 23	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Poliomyelitis vaccine	Inj 80D antigen units in 0.5 ml syringe	IPOL	2024
Poloxamer	Oral drops 10%, 30 ml OP	Coloxyl	2023
Posaconazole	Tab modified-release 100 mg	Posaconazole Juno	2025
Potassium iodate	Tab 253 mcg (150 mcg elemental iodine)	NeuroTabs	2023
Povidone iodine	Antiseptic solution 10%, 100 ml Oint 10%, 65 g OP	Riodone Betadine	2024 2023
Pramipexole hydrochloride	Tab 0.25 mg & 1 mg	Ramiprex	2025
Pravastatin	Tab 20 mg & 40 mg	Pravastatin Mylan	2023
Prednisolone	Oral liq 5 mg per ml, 30 ml OP	Redipred	2024
Prochlorperazine	Tab 5 mg	Nausafix	2023
Promethazine hydrochloride	Tab 10 mg & 25 mg	Allersoothe	2025
Propranolol	Tab 10 mg Tab 40 mg	Drofate IPCA-Propranolol	2024
Pyridoxine hydrochloride	Tab 25 mg	Vitamin B6 25	2023
Quetiapine	Tab 25 mg, 100 mg, 200 mg & 300 mg	Quetapel	2023
Quinapril	Tab 5 mg Tab 10 mg Tab 20 mg	Arrow-Quinapril 5 Arrow Quinapril 10 Arrow-Quinapril 20	2024
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 10 Accuretic 20	2024
Rifampicin	Cap 150 mg & 300 mg Oral liq 100 mg per 5 ml	Rifadin	2023
Rifaximin	Tab 550 mg	Xifaxan	2023
Riluzole	Tab 50 mg	Rilutek	2024
Risperidone	Tab 0.5 mg, 1 mg, 2 mg, 3 mg & 4 mg Oral liq 1 mg per ml	Risperidone (Teva) Risperon	2023
Rituximab	Inj 100 mg per 10 ml vial & 500 mg per 50 ml vial	Riximyo	30/09/2023
Rivastigmine	Patch 4.6 mg per 24 hour Patch 9.5 mg per 24 hour	Rivastigmine Patch BNM 5 Rivastigmine Patch BNM 10	2024
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	2023
Ropinirole hydrochloride	Tab 0.25 mg, 1 mg, 2 mg & 5 mg	Ropin	2025
Rosuvastatin	Tab 5 mg, 10 mg, 20 mg and 40 mg	Rosuvstatin Viatris	2023
Rotavirus oral vaccine	Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator	Rotarix	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Salbutamol	Oral liq 400 mcg per ml, 150 ml Nebuliser soln 1 mg per ml, 2.5 ml ampoule Nebuliser soln 2 mg per ml, 2.5 ml ampoule	Ventolin Asthalin	2024
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule	Duolin	2024
Sertraline	Tab 50 mg & 100 mg	Setrona	2025
Sildenafil	Tab 25 mg, 50 mg & 100 mg	Vedafil	2024
Simvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Simvastatin Mylan	2023
Sodium chloride	Inj 0.9%, 5 ml, 10 ml & 20 ml ampoule	Fresenius Kabi	2025
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2023
Sodium cromoglicate	Eye drops 2%, 10 ml OP	Allerfix	2025
Sodium fusidate [Fusidic acid]	Crn 2%, 5 g OP Oint 2%, 5 g OP	Foban	2024
Sodium hyaluronate [hyaluronic acid]	Eye drops 1 mg per ml, 10 ml OP	Hylo-Fresh	2024
Solifenacin succinate	Tab 5 mg & 10 mg	Solifenacin Mylan	2024
Somatropin (Omnitrope)	Inj 5 mg, 10 mg & 15 mg cartridge	Omnitrope	2024
Sotalol	Tab 80 mg & 160 mg	Mylan	2025
Spirolactone	Tab 25 mg & 100 mg	Spiractin	2025
Sumatriptan	Tab 50 mg & 100 mg	Sumagran	2024
Sunitinib	Cap 12.5 mg, 25 mg & 50 mg	Sunitinib Pfizer	2024
Sunscreens, proprietary	Lotn, 200 g OP	Marine Blue Lotion SPF lotn 50+	2025
Tacrolimus	Oint 0.1%, 30 g OP	Zematop	2023
Taliglucerase alfa	Inj 200 unit vial	Elelyso	2023
Tamoxifen citrate	Tab 10 mg & 20 mg	Tamoxifen Sandoz	2023
Tamsulosin	Cap 400 mcg	Tamsulosin-Rex	2025
Temazepam	Tab 10 mg	Normison	2023
Tenofovir disoproxil	Tab 245 mg (300 mg as a maleate)	Tenofovir Disoproxil Mylan	2025
Tenoxicam	Tab 20 mg	Tilcotil	2025
Terbinafine	Tab 250 mg	Deolate	2023
Teriflunomide	Tab 14 mg	Aubagio	2023
Tetrabenazine	Tab 25 mg	Motetis	2025
Thiamine hydrochloride	Tab 50 mg	Thiamine multichem	2025

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Ticagrelor	Tab 90 mg	Ticagrelor Sandoz	2024
Timolol	Eye drops 0.25% & 0.5%, 5 ml OP	Arrow-Timolol	2023
Tobramycin	Inj 40 mg per ml, 2 ml vial Solution for inhalation 60 mg per ml, 5 ml	Tobramycin Mylan Tobramycin BNM	2024 2023
Tramadol hydrochloride	Cap 50 mg Tab sustained-release 100 mg Tab sustained-release 150 mg Tab sustained-release 200 mg	Arrow-Tramadol Tramal SR 100 Tramal SR 150 Tramal SR 200	2023
Travoprost	Eye drops 0.004%, 2.5 ml OP	Travatan	2024
Tretinoin	Crn 0.5 mg per g, 50 g OP	ReTrieve	2024
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml ampoule Inj 40 mg per ml, 1 ml ampoule Paste 0.1%, 5 g OP Crn & oint 0.02%, 100 g OP	Kenacort-A 10 Kenacort-A 40 Kenalog in Orabase Aristocort	2023
Trimethoprim	Tab 300 mg	TMP	2024
Trimethoprim with sulphamethoxazole [co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	Trisul	2024
Tuberculin PPD [Mantoux] test	Inj 5 TU per 0.1 ml, 1 ml vial	Tubersol	2024
Ursodeoxycholic acid	Cap 250 mg	Ursosan	2023
Valaciclovir	Tab 500 mg & 1,000 mg	Valclovir	2024
Valganciclovir	Tab 450 mg	Valganciclovir Mylan	2024
Vancomycin	Inj 500 mg vial	Mylan	2023
Varenicline tartrate	Tab 0.5 mg x 11 and 1 mg x 42, 53 OP Tab 1 mg	Varenicline Pfizer	2024
Varicella vaccine [Chickenpox vaccine]	Inj 1350 PFU prefilled syringe	Varivax	2024
Water	Inj 20 ml ampoule	Fresenius Kabi	2025
Zoledronic acid	Inj 4 mg per 5 ml, vial	Zoledronic Acid Mylan	2024
Zopiclone	Tab 7.5 mg	Zopiclone Actavis	2024

April 2023 changes are in bold type

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 April 2023

8	GLYCOPYRRONIUM BROMIDE Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on a PSO.....	19.00	5	✓ Robinul
33	HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO..... Wastage claimable	2.46	3	✓ Cobal-B12 S29
46	WATER 1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops; or 4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only. Inj 10 ml ampoule – Up to 5 inj available on a PSO.....	7.60	50	✓ Multichem
47	ENALAPRIL MALEATE * Tab 5 mg..... * Tab 10 mg..... * Tab 20 mg..... Note – these are new listings for 90 tab packs.	1.75 1.97 2.35	90 90 90	✓ Acetec ✓ Acetec ✓ Acetec
107	DARUNAVIR – Special Authority see SA2139 – Retail pharmacy Tab 400 mg.....	132.00	60	✓ Darunavir Viatris
126	PHENYTOIN SODIUM * Tab 50 mg..... Note: this is a new Pharmacode listing, 2619474.	75.00	200	✓ Dilantin Infatab

New Listings – effective 1 April 2023 (continued)

228	ATEZOLIZUMAB – PCT only – Specialist – Special Authority see SA2195			
	Inj 60 mg per ml, 20 ml vial	9,503.00	1	✓ Tecentriq
	Inj 1 mg for ECP	8.08	1 mg	✓ Baxter

► SA2195 Special Authority for Subsidy

Initial application – (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with atezolizumab and met all remaining criteria below prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic non-small cell lung cancer; and
 - 2.2 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
 - 2.3 There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
 - 2.4 Patient has an ECOG 0-2; and
 - 2.5 Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and
 - 2.6 Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 12 weeks; and
 - 2.7 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal – (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent); and
- 6 Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings – effective 1 April 2023 (continued)

242	ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR – PCT only – Special Authority see SA2196		
	Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg and ivacaftor 75 mg	27,647.39	84 ✓ Trikafta
	Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg and ivacaftor 150 mg	27,647.39	84 ✓ Trikafta

► SA2196 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Patient is 6 years of age or older; and
- 3 Either:
 - 3.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
 - 3.2 Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and
- 4 Either:
 - 4.1 Patient has a heterozygous or homozygous F508del mutation; or
 - 4.2 Patient has a G551D mutation or other mutation responsive in vitro to elexacaftor/tezacaftor/ivacaftor (see note a); and
- 5 The treatment must be the sole funded CFTR modulator therapy for this condition; and
- 6 Treatment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition.

Notes:

- a) Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf.

244	CHLORAMPHENICOL		
	Eye drops 0.5%	1.45	10 ml OP ✓ Chlorsig
	Funded for use in the ear*. Indications marked with * are unapproved indications.		

Check your Schedule for full details Schedule page ref		Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	--	---------------------------------	-----	--

New Listings – effective 9 March 2023

33	HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO.....	2.46	3	✓ Vita-B12 S29
	Wastage claimable			

Effective 23 February 2023

147	CAPECITABINE – Retail pharmacy-Specialist Tab 500 mg.....	49.00	120	✓ Capecitabine-DRLA S29
	Wastage claimable			

Effective 20 February 2023

8	HYOSCINE BUTYLBROMIDE * Inj 20 mg, 1 ml – Up to 5 inj available on a PSO	6.35	5	✓ Buscopan S29 S29
	Wastage claimable			
124	FLUOXETINE HYDROCHLORIDE Cap 20 mg	2.22	30	✓ Brown & Burk S29
	Wastage claimable			

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions, Chemical Names and Presentations Effective 1 April 2023

34	PYRIDOXINE HYDROCHLORIDE (reinstate stat dispensing) a) No more than 100 mg per dose b) Only on a prescription * Tab 50 mg.....	23.45	500	✓ Pyridoxine multichem
38	FOLIC ACID (reinstate stat dispensing) * Tab 0.8 mg.....	26.60	1,000	✓ Folic Acid multichem
135	MELATONIN – Special Authority see SA1666 – Retail pharmacy (addition of age restriction) Tab modified-release 2 mg – No more than 5 tab per day.....	11.50	30	✓ <u>Vigisom</u>
	Restricted to patients under 18 years of age.			
230	PEMBROLIZUMAB – PCT only – Specialist – Special Authority see SA2197 2+2+ (amended Special Authority – new criteria shown only) Inj 25 mg per ml, 4 ml vial Inj 1 mg for ECP	4,680.00 47.74	1 1 mg	✓ Keytruda ✓ Baxter

► **SA2197 2+2+** Special Authority for Subsidy

Initial application – (non-small cell lung cancer first-line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or

2 All of the following:

- 2.1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2.2 Patient has not had chemotherapy for their disease in the palliative setting; and
- 2.3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 2.4 There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 2.5 Pembrolizumab to be used as monotherapy; and
- 2.6 Either:

2.6.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain; or

2.6.2 Both:

2.6.2.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain; and

2.6.2.2 Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment; and

2.7 Patient has an ECOG 0-2; and

2.8 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 12 weeks; and

2.9 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal – (non-small cell lung cancer first line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following

1 Any of the following:

1.1 Patient's disease has had a complete response to treatment; or

1.2 Patient's disease has had a partial response to treatment; or

1.3 Patient has stable disease; and

continued...

Changes to Restrictions – effective 1 April 2023 (continued)

continued...

- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application – (non-small cell lung cancer first-line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
 - 2.2 The patient has not had chemotherapy for their disease in the palliative setting; and
 - 2.3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
 - 2.4 There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
 - 2.5 Pembrolizumab to be used in combination with platinum-based chemotherapy; and
 - 2.6 Patient has an ECOG 0-2; and
 - 2.7 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 12 weeks; and
 - 2.8 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal – (non-small cell lung cancer first line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

246 TIMOLOL (addition of subsidy by endorsement)

- * Eye drops 0.5%, gel forming – Subsidy by endorsement 3.78 2.5 ml OP ✓ Timoptol XE
Subsidised for patients who were taking timolol eye drops 0.5%, gel forming prior to 1 April 2023 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of timolol eye drops 0.5%, gel forming.

246 DORZOLAMIDE HYDROCHLORIDE – Subsidy by endorsement (addition of subsidy by endorsement)

- Subsidised for patients who were taking dorzolamide hydrochloride eye drops 2% prior to 1 April 2023 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dorzolamide hydrochloride eye drops 2%.
* Eye drops 2% 9.77 5 ml OP
(17.44) Trusopt

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 April 2023 (continued)

- 278 INFLUENZA VACCINE (amended restriction criteria)
Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)
– [Xpharm] 11.00 1 ✓ **Afluria Quad Junior**
(2023 formulation)
- A) INFLUENZA VACCINE – child aged 6 months to 35 months
is available each year for patients aged 6 months to 35 months who meet the following criteria, as set
by Pharmac:
1 all children aged 6 months to 35 months from 1 April 2023 to 31 December 2023.
- i) have any of the following cardiovascular diseases
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebro-vascular disease; or
 - ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy; or
 - b) other chronic respiratory disease with impaired lung function; or
 - iii) have diabetes; or
 - iv) have chronic renal disease; or
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
 - vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) down syndrome, or
 - vii) have been hospitalised for respiratory illness or have a history of significant respiratory illness;
Unless meeting the criteria set out above, the following conditions are excluded from funding:
 - a) asthma not requiring regular preventative therapy,
 - b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Doctors are the only Contractors entitled to claim payment for the supply of influenza vaccine inj
30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) to patients eligible under the above criteria
for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the
Pharmaceutical Schedule.
- 278 INFLUENZA VACCINE (amended restriction criteria and addition of maximum of 1 inj per prescription)
Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) 110.00 10 ✓ **Afluria Quad**
(2023 formulation)
- a) Only on a prescription
 - b) No patient co-payment payable
 - c) Maximum of 1 inj per prescription**
 - A) INFLUENZA VACCINE – people 3 years and over
is available each year for patients aged 3 years and over who meet the following criteria, as set by
Pharmac:
 - a) all people 65 years of age and over; or

continued...

Changes to Restrictions – effective 1 April 2023 (continued)

continued...

- b) People 55 to 64 years of age (inclusive) and is Māori or of any Pacific ethnicity **from 1 April 2023 to 31 December 2023**; or
 - c) people under 65 years of age who:
 - i) have any of the following cardiovascular diseases:
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebo-vascular disease; or
 - ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function; or
 - iii) have diabetes; or
 - iv) have chronic renal disease; or
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
 - vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) Down syndrome, or
 - vii) are pregnant; or
 - d) children 3 and 4 years of age (inclusive) who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or
 - e) people under 65 years of age who:
 - i) have any of the following serious mental health conditions:
 - a) schizophrenia, or
 - b) major depressive disorder, or
 - c) bipolar disorder, or
 - d) schizo affective disorder, or
 - ii) are currently accessing secondary or tertiary mental health and addiction services; or
 - f) children 3 to 12 years of age (inclusive), from ~~1 July 2022 to 31 December 2022~~ **1 April 2023 to 31 December 2023**;
Unless meeting the criteria set out above, the following conditions are excluded from funding:
 - a) asthma not requiring regular preventative therapy,
 - b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Contractors will be entitled to claim payment for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 April 2023

8	SODIUM CROMOGLICATE (↑ subsidy) Cap 100 mg	113.35	100	✓ Ralicrom
33	BENZYDAMINE HYDROCHLORIDE (↑ price but not subsidy) Soln 0.15% – Higher subsidy of \$21.73 per 500 ml with endorsement	9.00 (21.73)	500 ml	Difflam
	Additional subsidy by endorsement for a patient who has oral mucositis as a result of treatment for cancer, and the prescription is endorsed accordingly.			
38	FOLIC ACID (↑ subsidy) Oral liq 50 mcg per ml	28.82	25 ml OP	✓ Biomed
44	HEPARIN SODIUM (↑ subsidy) Inj 5,000 iu per ml, 5 ml ampoule.....	350.40	50	✓ Pfizer
45	SODIUM BICARBONATE (↑ subsidy) Inj 8.4%, 50 ml	22.40	1	✓ Biomed
	a) Up to 5 inj available on a PSO			
	b) Not in combination			
	Inj 8.4%, 100 ml	22.95	1	✓ Biomed
	a) Up to 5 inj available on a PSO			
	b) Not in combination			
54	SPIRONOLACTONE (↑ subsidy) Oral liq 5 mg per ml	33.00	25 ml OP	✓ Biomed
80	DEXAMETHASONE (↑ subsidy) Oral liq 1 mg per ml	49.50	25 ml OP	✓ Biomed
90	MEBENDAZOLE – Only on a prescription (↑ price but not subsidy) Oral liq 100 mg per 5 ml	2.18 (7.83)	15 ml	Vermox
97	FLUCONAZOLE (↓ subsidy) Powder for oral suspension 10 mg per ml – Special Authority see SA1359 – Retail pharmacy..... Wastage claimable	109.34	35 ml	✓ Diflucan
119	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↑ subsidy) Oral (gel) soln 2%	44.00	200 ml	✓ Mucosoothe
126	LEVETIRACETAM (↑ subsidy) Tab 250 mg.....	5.84	60	✓ Everet
	Tab 500 mg.....	10.51	60	✓ Everet
	Tab 750 mg.....	16.71	60	✓ Everet
	Tab 1,000 mg.....	21.82	60	✓ Everet

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
✓ **fully subsidised**

Changes to Subsidy and Manufacturer's Price – effective 1 April 2023 (continued)

230	PEMBROLIZUMAB – PCT only – Specialist – Special Authority see SA2197 (↓ subsidy) Inj 1 mg for ECP	47.74	1 mg	✓ Baxter
236	CETIRIZINE HYDROCHLORIDE (↓ subsidy) * Tab 10 mg.....	1.71	100	✓ Zista

▲ Three months supply may be dispensed at one time if endorsed
“certified exemption” by the prescriber or pharmacist

* Three months or six months, as
applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 April 2023

8	SODIUM CROMOGLICATE Cap 100 mg	92.91	100	✓ Nalcrom
34	THIAMINE HYDROCHLORIDE – Only on a prescription * Tab 50 mg.....	7.09	100	✓ Max Health
54	CHLORTALIDONE [CHLORTHALIDONE] Tab 25 mg..... Wastage claimable	3.90	30	✓ Igroton S29
65	HYDROCORTISONE * Crm 1% – Only on a prescription.....	3.70	100 g OP	✓ Hydrocortisone (PSM)
65	HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription Crm 1% with natamycin 1% and neomycin sulphate 0.5%	3.35	15 g OP	✓ Pimafucort
66	AQUEOUS CREAM * Crm.....	1.73	500 g	✓ Evara
90	CEFACLOR MONOHYDRATE Cap 250 mg	24.70	100ml	✓ Ranbaxy-Cefaclor S29 S29
	Wastage claimable Grans for oral liq 125 mg per 5 ml – Wastage claimable.....	3.53	100 ml	✓ Ranbaxy-Cefaclor S29 S29
98	POSACONAZOLE – Special Authority see SA1285 – Retail pharmacy Tab modified-release 100 mg	869.86	24	✓ Noxafil
120	PARACETAMOL Oral liq 250 mg per 5 ml	6.25	1,000 ml	✓ Paracare Double Strength
	a) Maximum of 600 ml per prescription; can be waived by endorsement b) Up to 200 ml available on a PSO c) Not in combination d)			
	1) Maximum of 200 ml per dispensing for non-endorsed patients. If quantities prescribed exceed 200 ml (for non-endorsed patients), then dispense in repeat dispensing not exceeding 200 ml per dispensing. 2) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater and the prescription is endorsed or annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition.			
121	CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency Tab 30 mg..... Tab 60 mg.....	7.45 14.25	100 100	✓ PSM ✓ PSM

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items – effective 1 April 2023 (continued)

124	SERTRALINE				
	* Tab 50 mg.....	0.99	30	✓	Setrona AU
	* Tab 100 mg.....	1.74	30	✓	Setrona AU
	Note – Setrona AU tab 50 mg and 100 mg delisting delayed until 1 October 2023.				
130	LEVOMEPRMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
	Inj 25 mg per ml, 1 ml ampoule	33.50	10	✓	Nozinan
251	VANCOMYCIN ORAL SOLUTION (50 mg per ml)				
	Vancomycin 500 mg injection 10 vials				
	Glycerol BP 40 ml				
	Water to 100 ml				
	(Only funded if prescribed for treatment of Clostridium difficile following metronidazole failure)				

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 September 2023

8	GLYCOPYRRONIUM BROMIDE Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on a PSO.....	65.45	10	✓ Max Health
46	WATER 1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops; or 4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only. Inj 10 ml ampoule – Up to 5 inj available on a PSO.....	7.19	50	✓ Pfizer
Note: this delist applies to Pharmacodes 2511932 and 2549840				
47	ENALAPRIL MALEATE * Tab 5 mg..... * Tab 10 mg..... * Tab 20 mg.....	1.82 2.02 2.42	100 100 100	✓ Acetec ✓ Acetec ✓ Acetec
Note – these delists apply to 100 tab pack only.				
135	MIDAZOLAM – Safety medicine; prescriber may determine dispensing frequency Inj 1 mg per ml, 5 ml ampoule	3.95	10	✓ Midazolam Mylan
244	CHLORAMPHENICOL Eye drops 0.5%	7.50	10 ml OP	✓ Chlorafast
Funded for use in the ear*. Indications marked with * are unapproved indications.				

Effective 1 October 2023

26	MUCILAGINOUS LAXATIVES WITH STIMULANTS * Dry	6.02 (17.32) 2.41 (8.72)	500 g OP 200 g OP	Normacol Plus Normacol Plus
124	SERTRALINE * Tab 50 mg `..... * Tab 100 mg.....	0.99 1.74	30 30	✓ Setrona AU ✓ Setrona AU

Index

Pharmaceuticals and brands

A		
Acetec	20, 32	
Afluria Quad (2023 formulation)	26	
Afluria Quad Junior (2023 formulation)	26	
Aqueous cream	30	
Atezolizumab	21	
B		
Benzydamine hydrochloride	28	
Buscopan S29	23	
C		
Capecitabine	23	
Capecitabine-DRLA	23	
Cefaclor monohydrate	30	
Cetirizine hydrochloride	29	
Chlorafast	32	
Chloramphenicol	22, 32	
Chlorsig	22	
Chlortalidone [Chlorthalidone]	30	
Chlorthalidone	30	
Cobal-B12	20	
Codeine phosphate	30	
D		
Darunavir	20	
Darunavir Viatris	20	
Dexamethasone	28	
Difflam	28	
Diffucan	28	
Dilantin Infatab	20	
Dorzolamide hydrochloride	25	
E		
Elexacaftor with tezacaftor, ivacaftor and ivacaftor	22	
Enalapril maleate	20, 32	
Everet	28	
F		
Fluconazole	28	
Fluoxetine hydrochloride	23	
Folic acid	24, 28	
Folic Acid multichem	24	
G		
Glycopyrronium bromide	20, 32	
H		
Heparin sodium	28	
Hydrocortisone	30	
Hydrocortisone (PSM)	30	
Hydrocortisone with natamycin and neomycin	30	
Hydroxocobalamin	20, 23	
Hyoscine butylbromide	23	
I		
Igrotan	30	
Influenza vaccine	26	
K		
Keytruda	24	
L		
Levetiracetam	28	
Levomepromazine hydrochloride	31	
Lidocaine [Lignocaine] hydrochloride	28	
Lignocaine	28	
M		
Mebendazole	28	
Melatonin	24	
Midazolam	32	
Midazolam Mylan	32	
Mucilaginous laxatives with stimulants	32	
Mucosoothe	28	
N		
Nalcrom	30	
Normacol Plus	32	
Noxafil	30	
Nozinan	31	
P		
Paracare Double Strength	30	
Paracetamol	30	
Pembrolizumab	24, 29	
Phenytoin sodium	20	
Pimafucort	30	
Posaconazole	30	
Pyridoxine hydrochloride	24	
Pyridoxine multichem	24	
R		
Ralicrom	28	
Ranbaxy-Cefaclor S29	30	
Robinul	20	
S		
Sertraline	31, 32	
Setrona AU	31, 32	
Sodium bicarbonate	28	
Sodium cromoglicate	28, 30	
Spironolactone	28	
T		
Tecentriq	21	
Thiamine hydrochloride	30	
Timolol	25	
Timoptol XE	25	
Trikafta	22	
Trusopt	25	
V		
Vancomycin oral solution	31	
Vermox	28	
Vigisom	24	

Index

Pharmaceuticals and brands

Vita-B12 23

W

Water..... 20, 32

Z

Zista 29

